User profiles for Pragya Yadav
 | Pragya D YadavScientist Verified email at gov.in Cited by 10046 |
[HTML][HTML] Full-genome sequences of the first two SARS-CoV-2 viruses from India
Methods: Throat swab/nasal swab specimens for a total of 881 suspected cases were
screened by E gene and confirmed by RdRp (1), RdRp (2) and N gene real-time reverse …
screened by E gene and confirmed by RdRp (1), RdRp (2) and N gene real-time reverse …
CRISPR-Cas9 mediated genome editing of drought and salt tolerance (OsDST) gene in indica mega rice cultivar MTU1010
…, RK Verma, SK Yadav, P Yadav… - … and Molecular Biology …, 2020 - Springer
Abstract Development of abiotic stress tolerant rice cultivars is necessary for sustainable rice
production under the scenario of global climate change, dwindling fresh water resources …
production under the scenario of global climate change, dwindling fresh water resources …
[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …
…, D Raju, U Praturi, G Sapkal, P Yadav… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
[HTML][HTML] Carbon nanotubes: an emerging drug carrier for targeting cancer cells
V Rastogi, P Yadav, SS Bhattacharya… - Journal of drug …, 2014 - hindawi.com
During recent years carbon nanotubes (CNTs) have been attracted by many researchers as
a drug delivery carrier. CNTs are the third allotropic form of carbon-fullerenes which were …
a drug delivery carrier. CNTs are the third allotropic form of carbon-fullerenes which were …
[HTML][HTML] Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
The COVID-19 pandemic is a global health crisis that poses a great challenge to the public
health system of affected countries. Safe and effective vaccines are needed to overcome this …
health system of affected countries. Safe and effective vaccines are needed to overcome this …
[HTML][HTML] Detection, isolation and confirmation of Crimean-Congo hemorrhagic fever virus in human, ticks and animals in Ahmadabad, India, 2010–2011
DT Mourya, PD Yadav, AM Shete… - PLoS neglected …, 2012 - journals.plos.org
Background In January 2011, human cases with hemorrhagic manifestations in the hospital
staff were reported from a tertiary care hospital in Ahmadabad, India. This paper reports a …
staff were reported from a tertiary care hospital in Ahmadabad, India. This paper reports a …
[HTML][HTML] Imported SARS-CoV-2 V501Y. V2 variant (B. 1.351) detected in travelers from South Africa and Tanzania to India
The SARS-CoV-2 has been continuously mutating, leading to the emergence of new variant
strains since the emergence of the pandemic (2020–21). The first SARS-CoV-2 variant, 20I/…
strains since the emergence of the pandemic (2020–21). The first SARS-CoV-2 variant, 20I/…
Neutralization of variant under investigation B. 1.617. 1 with sera of BBV152 vaccinees
To the Editor—The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants in places where the virus is uncontained poses a global threat from the …
variants in places where the virus is uncontained poses a global threat from the …
[HTML][HTML] SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
expands, genomic epidemiology and whole genome sequencing are being used to investigate …
expands, genomic epidemiology and whole genome sequencing are being used to investigate …
[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …